Sanofi (NASDAQ: SNY) reported Q2 EPS of EUR1.28, EUR0.07 better than the analyst estimate of EUR1.21. Revenue for the quarter came in at EUR8.21 billion versus the consensus estimate of EUR8.39 billion.

Full-year 2020 business EPS(1) guidance revised upward:

Sanofi now expects 2020 business EPS(1) to grow between 6% and 7%(4) at CER, barring unforeseen major adverse events. Applying average July 2020 exchange rates, the currency impact on 2020 business EPS is estimated to be between -3% to -4%.

For earnings history and earnings-related data on Sanofi (SNY) click here.